Noopept stimulates the expression of NGF and BDNF in rat hippocampus
- 632 Downloads
We studied the effect of original dipeptide preparation Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111) with nootropic and neuroprotective properties on the expression of mRNA for neurotropic factors NGF and BDNF in rat hippocampus. Expression of NGF and BDNF mRNA in the cerebral cortex and hippocampus was studied by Northern blot analysis. Taking into account the fact that pharmacological activity of Noopept is realized after both acute and chronic treatment, we studied the effect of single and long-term treatment (28 days) with this drug. Expression of the studied neurotropic factors in the cerebral cortex was below the control after single administration of Noopept, while chronic administration caused a slight increase in BDNF expression. In the hippocampus, expression of mRNA for both neurotrophins increased after acute administration of Noopept. Chronic treatment with Noopept was not followed by the development of tolerance, but even potentiated the neurotrophic effect. These changes probably play a role in neuronal restoration. We showed that the nootropic drug increases expression of neurotrophic factors in the hippocampus. Our results are consistent with the hypothesis that neurotrophin synthesis in the hippocampus determines cognitive function, particularly in consolidation and delayed memory retrieval. Published data show that neurotrophic factor deficiency in the hippocampus is observed not only in advanced Alzheimer's disease, but also at the stage of mild cognitive impairment (predisease state). In light of this our findings suggest that Noopept holds much promise to prevent the development of Alzheimer's disease in patients with mild cognitive impairment. Moreover, therapeutic effectiveness of Noopept should be evaluated at the initial stage of Alzheimer's disease.
Key WordsNoopept neurotrophic factors hippocampus Alzheimer's disease
Unable to display preview. Download preview PDF.
- 2.A. P. Bel'nik, R. U. Ostrovskaya, and I. I. Poletaeva, Ibid., 143, No. 4, 407–410 (2007).Google Scholar
- 3.T. A. Zenina, T. A. Gudasheva, Ya. S. Bukreev, and S. B. Seredenin, Ibid., 144, No. 10, 424–426 (2007).Google Scholar
- 4.G. M. Molodavkin, G. G. Borlikova, T. A. Voronina, et al., Eksper. Klin. Farmakol., 65, No. 2, 3–5 (2002).Google Scholar
- 5.R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, and S. B. Seredenin, Ibid., 65, No. 5, 66–72 (2002).Google Scholar
- 6.R. U. Ostrovskaya, A. P. Bel'nik, and Z. I. Storozheva, Byull. Eksp. Biol. Med., 146, No. 7, 84–89 (2008).Google Scholar
- 7.A. N. Chepkova, S. S. Trofimov, N. M. Smol'nikova, et al., Ibid., 120, No. 12, 592–595 (1995).Google Scholar